BioNTech (NASDAQ:BNTX) Rating Increased to Overweight at Morgan Stanley

BioNTech (NASDAQ:BNTX) was upgraded by research analysts at Morgan Stanley from an “equal weight” rating to an “overweight” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports. The firm currently has a $145.00 price target on the stock, up from their prior price target of $93.00. Morgan Stanley’s price objective would indicate a potential upside of 25.22% from the company’s previous close.

Other equities analysts have also issued reports about the stock. HC Wainwright restated a “buy” rating and issued a $113.00 price objective on shares of BioNTech in a report on Monday, September 16th. TD Cowen lowered their price target on BioNTech from $98.00 to $85.00 and set a “hold” rating for the company in a research report on Tuesday, August 6th. JPMorgan Chase & Co. upgraded BioNTech from an “underweight” rating to a “neutral” rating and boosted their price objective for the company from $91.00 to $125.00 in a report on Monday, September 16th. UBS Group increased their target price on BioNTech from $97.00 to $131.00 and gave the stock a “neutral” rating in a research note on Wednesday, September 18th. Finally, Bank of America lifted their target price on BioNTech from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Monday, September 16th. Five equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $127.15.

BioNTech Trading Down 2.3 %

BNTX opened at $115.80 on Tuesday. The business’s 50 day moving average price is $92.60 and its 200 day moving average price is $91.14. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.40 and a current ratio of 7.54. The stock has a market capitalization of $27.53 billion, a PE ratio of 231.60 and a beta of 0.23. BioNTech has a one year low of $76.53 and a one year high of $131.49.

BioNTech (NASDAQ:BNTX) last announced its quarterly earnings results on Monday, August 5th. The company reported ($3.36) EPS for the quarter, missing the consensus estimate of ($2.02) by ($1.34). The business had revenue of $128.70 million during the quarter, compared to analyst estimates of $134.98 million. BioNTech had a negative net margin of 18.69% and a negative return on equity of 2.54%. The business’s revenue for the quarter was down 23.3% on a year-over-year basis. During the same period last year, the company earned ($0.86) EPS. As a group, equities research analysts expect that BioNTech will post -2.87 EPS for the current year.

Institutional Trading of BioNTech

Institutional investors have recently bought and sold shares of the business. Candriam S.C.A. raised its position in shares of BioNTech by 261.2% during the 2nd quarter. Candriam S.C.A. now owns 578,998 shares of the company’s stock worth $46,526,000 after acquiring an additional 418,695 shares in the last quarter. US Bancorp DE boosted its holdings in shares of BioNTech by 420.7% in the 4th quarter. US Bancorp DE now owns 28,614 shares of the company’s stock valued at $3,020,000 after buying an additional 23,119 shares in the last quarter. Goldman Sachs Group Inc. grew its position in shares of BioNTech by 17.2% in the 4th quarter. Goldman Sachs Group Inc. now owns 182,878 shares of the company’s stock valued at $19,301,000 after buying an additional 26,777 shares during the last quarter. Harding Loevner LP acquired a new stake in BioNTech during the 4th quarter worth $410,984,000. Finally, Discovery Capital Management LLC CT purchased a new stake in BioNTech in the second quarter valued at $2,467,000. 15.52% of the stock is owned by hedge funds and other institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.